이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Humanwell Healthcare (Group)Ltd 관리

관리 기준 확인 2/4

Humanwell Healthcare (Group)Ltd's CEO는 Xiafei Deng, Jun2020 에 임명되었습니다 의 임기는 25.33 년입니다. 는 CN¥ 28.94M 가치에 해당하는 회사 주식의 0.098% 직접 소유합니다. 28.94M. 경영진과 이사회의 평균 재임 기간은 각각 4.2 년과 8.6 년입니다.

주요 정보

Xiafei Deng

최고 경영자

CN¥7.2m

총 보상

CEO 급여 비율	n/a
CEO 임기	4.1yrs
CEO 소유권	0.1%
경영진 평균 재임 기간	4.3yrs
이사회 평균 재임 기간	8.7yrs

최근 관리 업데이트

Recent updates

Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement

May 22

CEO

Xiafei Deng (60 yo)

4.1yrs

테뉴어

CN¥7,185,300

보상

Mr. Xiafei Deng serves as President at Humanwell Healthcare (Group) Co.,Ltd. since June 2020. He serves as Director of Wuhan Humanwell Healthcare (Group) Co.,Ltd.and served as its Vice President until Jun...

리더십 팀

이름	위치	테뉴어	보상	소유권
Xiafei Deng	President & Director	4.1yrs	CN¥7.19m	0.098% CN¥ 26.7m
Yajun Wu	CFO & VP	20.3yrs	CN¥2.08m	0.059% CN¥ 16.2m
Qianlun Li	VP & Secretary	11.2yrs	CN¥1.97m	0.019% CN¥ 5.1m
Wentao Du	Vice President	20.8yrs	CN¥4.07m	0.056% CN¥ 15.2m
Lie Li	Vice President	4.3yrs	CN¥3.70m	0.032% CN¥ 8.7m
Hongjie Zhang	Vice President	no data	CN¥4.97m	0.028% CN¥ 7.6m
Qiang Yin	Vice President	4.3yrs	CN¥1.97m	0.028% CN¥ 7.6m
Qun Yu	Vice President	3.8yrs	CN¥3.69m	0.028% CN¥ 7.6m

4.3yrs

평균 재임 기간

54.5yo

평균 연령

경험이 풍부한 관리: 600079 의 관리팀은 경험 ( 4.2 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Xiafei Deng	President & Director	25.4yrs	CN¥7.19m	0.098% CN¥ 26.7m
Min Qi	Supervisor	10.2yrs	데이터 없음	데이터 없음
Rui Zhou	Independent Director	3.2yrs	CN¥100.00k	데이터 없음
Lin Qing Liu	Independent director	4.2yrs	CN¥100.00k	데이터 없음
Xiao Dong Zhang	Director	27.5yrs	CN¥1.81m	0.029% CN¥ 7.8m
Xuehai Wang	Director	21.2yrs	CN¥618.50k	0.22% CN¥ 61.4m
Jie Li	Chairman of the Board	21.2yrs	CN¥5.67m	6.06% CN¥ 1.7b
Yue Xin Du	Chairman of the Supervisory Board	19.3yrs	CN¥66.00k	데이터 없음
Hansheng Zhou	Director	7.3yrs	CN¥1.81m	데이터 없음
Chenggang Zheng	Supervisor	4.2yrs	데이터 없음	데이터 없음
Kong Na	Representative Member of the Supervisory Board	4.2yrs	데이터 없음	데이터 없음
Xia Yuan	Employee Representative Member of the Supervisory Board	4.2yrs	데이터 없음	데이터 없음

8.7yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: 600079 의 이사회는 경험(평균 재직 기간 8.6 년)으로 간주됩니다.

Humanwell Healthcare (Group)Ltd 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Dividend of CN¥0.46 announced

Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Investor sentiment improves as stock rises 17%

Humanwell Healthcare (Group) Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Novo Holdings A/S agreed to acquire The Ritedose Corporation from AGIC Capital, Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) and others.

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

Price target decreased to CN¥33.31

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥25.74

Investor sentiment deteriorated over the past week

New 90-day low: CN¥27.26

New 90-day low: CN¥30.20

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥30.82

Analysts update estimates

Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) entered into a preliminary letter of intent to acquire an additional 13% stake in YiChang Humanwell Pharmaceutical Co., Ltd from Li Jie, Chen Xiaoqing, and Xu Huabin.

Price target lowered to CN¥10.32

New 90-day high - CN¥38.00

New 90-day high - CN¥36.85

Chongqing Pharmaceutical (Group) Co., Ltd. signed the Sichuan Humanwell Pharmaceutical Co., Ltd. Equity Transfer Contract to acquire 70% stake in Sichuan Humanwell Pharmaceutical Co., Ltd from Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) for approximately CNY 360 million.

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령